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Abstract
The onset of clinical assisted reproduction, a quarter of a century ago, required the isolation of
motile spermatozoa. As the indication of assisted reproduction shifted from mere gynaecological
indications to andrological indications during the years, this urged andrological research to
understand the physiology of male germ cell better and develop more sophisticated techniques to
separate functional spermatozoa from those that are immotile, have poor morphology or are not
capable to fertilize oocytes. Initially, starting from simple washing of spermatozoa, separation
techniques, based on different principles like migration, filtration or density gradient centrifugation
evolved. The most simple and cheapest is the conventional swim-up procedure. A more
sophisticated and most gentle migration method is migration-sedimentation. However, its yield is
relatively small and the technique is therefore normally only limited to ejaculates with a high
number of motile spermatozoa. Recently, however, the method was also successfully used to
isolate spermatozoa for intracytoplasmic sperm injection (ICSI). Sperm separation methods that
yield a higher number of motile spermatozoa are glass wool filtration or density gradient
centrifugation with different media. Since Percoll® as a density medium was removed from the
market in 1996 for clinical use in the human because of its risk of contamination with endotoxins,
other media like IxaPrep®, Nycodenz, SilSelect®, PureSperm® or Isolate® were developed in order
to replace Percoll®. Today, an array of different methods is available and the selection depends on
the quality of the ejaculates, which also includes production of reactive oxygen species (ROS) by
spermatozoa and leukocytes. Ejaculates with ROS production should not be separated by means
of conventional swim-up, as this can severely damage the spermatozoa. In order to protect the
male germ cells from the influence of ROS and to stimulate their motility to increase the yield, a
number of substances can be added to the ejaculate or the separation medium. Caffeine,
pentoxifylline and 2-deoxyadenosine are substances that were used to stimulate motility. Recent
approaches to stimulate spermatozoa include bicarbonate, metal chelators or platelet-activating
factor (PAF). While the use of PAF already resulted in pregnancies in intrauterine insemination, the
suitability of the other substances for the clinical use still needs to be tested. Finally, the isolation
of functional spermatozoa from highly viscous ejaculates is a special challenge and can be performed
enzymatically to liquefy the ejaculate. The older method, by which the ejaculate is forcefully
aspirated through a narrow-gauge needle, should be abandoned as it can severely damage
spermatozoa, thus resulting in immotile sperm.
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Introduction
Since the birth of Louise Brown on 25 July 1978 and the
subsequent onset of assisted reproduction in the human,
scientists and clinicians were more and more urged to
improve sperm separation techniques as the percentage of
andrological cases increased rapidly. While the first in vitro
fertilization (IVF) cases, including that of Louise Brown,
were performed to treat tubal infertility, the increasing
number of men showing poor semen quality prompted
the development of a wide array of different laboratory
techniques focusing on the selection and enrichment of
motile and functionally competent spermatozoa from the
ejaculate. The first sperm separation methods available
only comprised of one or two washing procedures with
subsequent resuspension of the male germ cells [1-3].
Mahadevan and Baker [4] then described a single wash
followed by a swim-up procedure from the cell pellet. Fol-
lowing these first reports on human sperm separation,
more sophisticated methods were developed to obtain
sufficient amounts of motile, functionally competent
spermatozoa for IVF. Eventually, methods were developed
that improved sperm functions like motility, protected
sperm functions and/or reduced detrimental effects from
the environmental milieu like reactive oxygen species.
In this paper, we aimed at giving an update on the main
sperm separation methods including their implications
and importance for modern assisted reproductive tech-
nologies as well as an overview on different in vitro treat-
ments of spermatozoa to improve their functional
competence and to reduce detrimental effects.
Sperm separation techniques
Under in vivo conditions, potentially fertile spermatozoa
are separated from immotile spermatozoa, debris and
seminal plasma in the female genital tract by active migra-
tion through the cervical mucus [5]. During this process,
not only progressively motile spermatozoa are selected,
but male germ cells also undergo physiological changes
called capacitation, which are fundamental prerequisites
for the sperm's functional competence with regard to
acrosome reaction [6,7].
The introduction of assisted reproduction, especially of
IVF, during the 1980's, led to the development of a wide
range of different sperm separation methods. Following
the development of the classical swim-up method by
Mahadevan & Baker [4], more complicated techniques
were developed to increase the number of motile sperma-
tozoa even in severe andrological cases. On principle,
these techniques can be differentiated in migration, den-
sity gradient centrifugation and filtration techniques. For
all migration methods, the self-propelled movement of
spermatozoa is an essential prerequisite, while for density
gradient centrifugation and filtration techniques the
methodology is based on a combination of the sperm
cells' motility and their retention at phase borders and
adherence to filtration matrices, respectively. The migra-
tion techniques can again be subdivided into swim-up,
under-lay and migration-sedimentation methods [8,9].
For density gradient centrifugation, separation media like
Ficoll® [10], Nycodenz [11] and Percoll® [12,13] including
the products (IxaPrep®, PureSperm®, Isolate®, SilSelect®)
have recently been introduced to replace Percoll® [14,15].
The filtration methods like glass wool filtration [16,17]
and filtration of spermatozoa on Sephadex beads [18] and
membranes [19] are alternative techniques.
The ideal sperm separation technique should (i) be quick,
easy and cost-effective, (ii) isolate as much motile sperma-
tozoa as possible, (iii) not cause sperm damage or non-
physiological alterations of the separated sperm cells, (iv)
eliminate dead spermatozoa and other cells, including
leukocytes and bacteria, (v) eliminate toxic or bioactive
substances like decapacitation factors or reactive oxygen
species (ROS), and (vi) allow processing of larger volumes
of ejaculates. Since none of the methods available meets
all these requirements, a variety of sperm separation tech-
niques is mandatory in clinical practice to obtain an opti-
mal yield of functionally competent spermatozoa for
insemination purposes. Depending on the ejaculate qual-
ity, these methods have different efficiency and areas of
use. In the conventional swim-up technique, functional
spermatozoa can come into close cell-to-cell contact with
defective sperm or leukocytes by centrifugation, thus caus-
ing massive oxidative damages of the sperm plasma mem-
brane by ROS and consequently of sperm functions [20].
Therefore, the quality of the ejaculates has direct conse-
quences on the choice of a sperm separation method.
Table 1: Advantages and disadvantages of the conventional swim-up method.
Advantages Disadvantages
- easy to perform - restricted to ejaculates with high sperm count and motility
- very cost-effective
- usually recovery of a very clean fraction of highly motile spermatozoa - low yield
- spermatozoa can be massively damaged by reactive oxygen species
- significant decrease of the percentage of normally chromatin-
condensed spermatozoaReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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With regard to the possible risk of a seroconversion in
women and in the offspring after performing ART with
spermatozoa from a HIV-positive man initial concerns
arose as HIV viruses reportedly can bind to and penetrate
into spermatozoa [21,22]. Later research, however,
showed that HIV-1 genomes found to an extend of 18%
in seminal cells samples decreased to undetectable levels
following a combined density gradient centrifugation
with a subsequent swim-up [23]. No seroconversion of
the virus could be observed after fertilization of oocytes by
IVF-ICSI [24-26]. Other recent research [27] showed that
HIV RNA and DNA could be detected in separated sper-
matozoa even in treated patients. Thus, viral validation of
separated spermatozoa is necessary and should be per-
formed even in treated patients. Additionally, only HIV-
tested maternal serum or commercially available serum
albumin, which is HIV-free due to its processing, should
be used as protein supplement for culture media.
In order to give an overview, only the four most common
techniques classical swim-up, migration-sedimentation,
density gradient centrifugation and glass wool filtration
are discussed.
Swim-up procedure
Apart from a simple wash and subsequent resuspension of
the male germ cells, the swim-up from a washed pellet is
the oldest and most commonly used sperm separation
method. Originally described by Mahadevan and Baker
[4], this method is still used largely in IVF laboratories
around the world. Although its use among the male factor
infertility group is very limited, the swim-up is still the
standard technique for patients with normozoospermia
and female infertility. Excellent fertilization rates were
reported when these sperm preparations were used to
inseminate human oocytes in vitro. However, as the indi-
cations for IVF were expanded beyond simple tubal factor
cases to couples with idiopathic infertility and, ultimately,
to male factor cases, the problem of fertilization failure
appeared [28-30].
The methodology of this conventional swim-up is based
on the active movement of spermatozoa from the pre-
washed cell pellet into an overlaying medium. Typically,
the incubation time is 60 minutes. This technique is dis-
tinguished by a very high percentage (>90%) of motile
sperm, preferred enrichment of morphologically normal
spermatozoa as well as the absence of other cells and
debris. Considering that the efficiency of the technique is
based on the surface of the cell pellet and the initial sperm
motility in the ejaculate, the yield of motile spermatozoa
is limited. Many layers of cells in the pellet may cause
potentially motile spermatozoa in the lower levels of the
pellet never to reach the interface with the culture
medium layer. In addition, a significant decrease in the
percentage of normally chromatin-condensed spermato-
zoa has been reported after the swim-up procedure [31].
Another major disadvantage of this technique is the fact
that for its use spermatozoa are pelleted, thus coming into
close cell-to-cell contact with each other, cell debris and
leukocytes, which are known to produce very high levels
of reactive oxygen species (ROS) [32]. Due to the extraor-
dinary high amount of poly-unsaturated fatty acids in the
sperm's plasma membranes [33], these ROS cause lipid
peroxidation and therefore a dramatic decrease in sperm
functions, including motility [34]. Overall, although
many men's spermatozoa may not be impaired to the
extent of inhibiting fertilization, some couples' chances of
successful IVF will certainly be compromised. It is there-
fore not reasonable to continue and to use a technique,
such as swim-up from pelleted semen with the inherent
potential to cause irrevocable damage to spermatozoa
prejudicial to a desired functional endpoint. Eventually,
this knowledge led to the development of other more gen-
tle sperm separation methods that also allow a higher
recovery of motile and functional spermatozoa. The
advantages and disadvantages of the conventional swim-
up are summarized in table 1.
An attempt to overcome at least the problems caused by
ROS, the "swim-up" can be performed directly from the
liquefied semen. During this procedure, several aliquots
of liquefied semen are taken from a sample and placed in
tubes underneath an overlay of culture medium. Round-
bottom tubes or 4-well dishes should be used to optimize
the surface area of the interface between the semen layer
and the culture medium. The tubes may also be prepared
by gently layering culture medium over the liquefied
semen. The placing of semen underneath the culture
medium, however, provides a much cleaner interface
zone. A maximum recovery is obtained by using multiple
tubes with small volumes of semen per tube, thus maxi-
mizing the combined total interface area between semen
and culture medium. Mortimer [35] suggested the use of
250 µl semen and 500 to 600 µl culture medium per tube.
After the incubation period, which is typically between 30
and 60 minutes, at 37°C, most of the upper culture
medium layer is removed. This should be done with cau-
tion, working from the upper meniscus downwards, using
a sterile pipette. Typically, 75 or 80% of the culture
medium layer are removed and eventually combined,
taking great care not to aspirate directly from the interface
region. This procedure will also increase the total number
of recovered spermatozoa, which can then also be used for
ICSI [36].
Other swim-up methods include the swim-up of sperma-
tozoa in a specially supplemented medium. Such sub-
stances can be SpermSelect™, which is a highly purified
preparation of hyaluronic acid (Pharmacia, Uppsala,Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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Sweden) with an average molecular weight of 3,000 kDa
that was used at a final concentration of 1 mg/ml in cul-
ture medium. Compared with the traditional swim-up
from a washed pellet [37], a swim-up directly from semen
into a hyaluronic acid solution gave a significantly higher
percentage of motile spermatozoa and, ultimately, the
achievement of a higher pregnancy rate in a clinical IVF
program [38]. However, highly purified hyaluronic acid is
expensive and it has been shown to increase the calcium-
influx into spermatozoa and therefore induce acrosome
reaction [39]. Elevated local concentrations of hyaluronic
acid in the cumulus oophorus have been shown to con-
tribute to the acrosome reaction [40]. Thus, it seems rather
questionable whether this substance is favourable for IVF.
In addition, whether these improved results in sperm
motility were specifically due to the use of the hyaluronate
or to the use of a method, which did not involve the initial
pelletting of unselected spermatozoa, has not been ascer-
tained. On the other hand, however, hyaluronic acid has
been regarded as an effective alternative to test sperm pen-
etration into human cervical mucus [41-43].
Migration-sedimentation
A more sophisticated sperm separation technique is
migration-sedimentation, which was developed by Tea et
al. [8]. Principally, this method is a swim-up technique
combined with a sedimentation step. Special glass or plas-
tic tubes with an inner cone are used. In contrast to the
conventional swim-up procedure, spermatozoa swim up
directly from liquefied semen into the supernatant
medium and subsequently sediment in that inner cone
within an hour's time. Thus, this method is a highly gentle
technique, especially if compared with methods that
require centrifugation steps before the sperm separation
like the conventional swim-up. In the original version, a
fraction of highly motile and functionally competent
spermatozoa can be obtained. Unfortunately, the yield is
very low and therefore the original method did not find
wide acceptance for IVF. The advantages and disadvan-
tages of this method are summarized in table 2. Recently,
Zavos et al. [9] proposed the use of a multi-chamber tube
to retrieve functional spermatozoa for assisted reproduc-
tive techniques by means of a swim-up and sedimentation
method. The assessment of its usefulness for IVF/ICSI,
however, is still to be awaited.
Sánchez et al. [44] showed that after concentration of
sperm cells in the ejaculate, even in cases with severe
oligo- and/or asthenozoospermia a sufficient number of
motile spermatozoa can be isolated for intracytoplasmic
sperm injection (ICSI) after 2–3 hours of incubation.
Compared with the density gradient centrifugation, these
authors also demonstrated significantly better results for
progressive motility, normal sperm morphology, chroma-
tin condensation and reduction of the percentage of dead
spermatozoa as determined by the eosin test. In addition,
since spermatozoa isolated by this modified migration-
sedimentation technique stick markedly less to the glass
surface of the injection pipettes, this method has even an
advantage over the density gradient centrifugation, which
Table 2: Advantages and disadvantages of the original migration-sedimentation method according to Tea et al. (1984).
Advantage Disadvantages
- usually very clean fraction of highly motile spermatozoa - the original method is restricted to ejaculates of high sperm count and good motility
- reactive oxygen species are reduced - the original method has a very low recovery rate
- very gentle separation method
- special glass or plastic tubes are required
- tubes are more expensive and relatively sensitive
- for repeated use in IVF, glass and plastic tubes must be sterilized
Table 3: Advantages and disadvantages of density gradient centrifugation.
Advantages Disadvantages
- usually clean fraction of highly motile spermatozoa - production of good interphases between the different media is a bit 
more time-consuming
- spermatozoa from ejaculates with a very low sperm density can be 
separated
- a bit more expensive
- good yield - potential risk of endotoxins
- leukocytes are eliminated to a large extent - Percoll® may no longer be used IVF/ICSI
- reactive oxygen species are significantly reducedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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is normally used for these cases. In this regard, the side
migration technique that was recently proposed by Hint-
ing and Lunardhi [45] is another interesting approach to
obtain motile spermatozoa from very poor quality semen
for ICSI as it also yielded better sperm quality.
Density gradient centrifugation
The typical methodology for the density gradient centrifu-
gation comprised continuous [46] or discontinuous gra-
dients [47]. With continuous gradients, there is a gradual
increase in density from the top of the gradient to its bot-
tom, whereas the layers of a discontinuous gradient show
clear boundaries between each other. The ejaculate is
placed on top of the density media with higher density
and is then centrifuged for 15–30 minutes. During this
procedure, all cells reach the semen sediment. However,
highly motile spermatozoa move actively in the direction
of the sedimentation gradient and can therefore penetrate
the boundary quicker than poorly motile or immotile
cells, thus, highly motile sperm cells are enriched in the
soft pellet at the bottom.
A wide variety of methods using the principle of density
gradient centrifugation to fractionate subpopulations of
spermatozoa has been described in the literature. Ficoll®
has initially been used as gradient material for preparing
spermatozoa [48], but by far the most widely used sub-
stance for all methods of assisted reproduction (IUI, GIFT,
IVF, ICSI, etc.) have been the polyvinylpyrrolidone (PVP)-
coated silica particles Percoll®. Normal sperm function in
terms of sperm fertilizing ability as assessed in the zona
pellucida-free hamster egg penetration test [20,49], as
well as in human IVF [13] and ICSI [50] was observed. In
October 1996, Percoll® has been withdrawn from the mar-
ket for clinical use in assisted reproduction [51]. This was
because of the risk of contaminations with endotoxins
[52-54], possible membrane alteration [55,56] and
inflammatory responses that could be induced by the
insemination of sperm populations contaminated with
Percoll®. In addition, Percoll® adheres to the sperm mem-
branes [57] and might alter them by removing coating
envelopes [58]. Therefore, intensive washing of the sper-
matozoa after sperm separation with Percoll® was recom-
mended [55]. This requires additional centrifugation and
can again be detrimental to the spermatozoa because of
the action of reactive oxygen species [20].
Another commercial product known as Nycodenz (Nye-
gaard & Co., Oslo, Norway) was also used as a density gra-
dient material for preparing human spermatozoa.
Nycodenz is the same molecule, iohexol, as used in the X-
ray contrast medium Omni-paque. Studies revealed a low
incidence of adverse reactions during angiography [11].
Both continuous and discontinuous Nycodenz gradients
were evaluated, of which a four-layer discontinuous gradi-
ent was found to produce populations of highly motile
spermatozoa with better yields and survival than either
swim-up or Percoll® gradients from oligozoospermic and
asthenozoospermic semen samples [11,59]. Compared
with the conventional swim-up procedure from a pelleted
sperm population, the use of Nycodenz also seems to be
superior regarding sperm penetration into zona-free ham-
ster eggs [60]. Thus, this technique has clearly great poten-
tial in the preparation of motile spermatozoa from poor
quality semen for IVF use and warrants further
investigation.
Other replacement products for Percoll® that were intro-
duced into the market from the mid nineties and more
commonly used in assisted reproduction are IxaPrep®
(MediCult, Copenhagen, Denmark), SilSelect® (FertiPro
N.V., Beernem, Belgium), PureSperm® (NidaCon Labora-
tories AB, Gothenburg, Sweden) or ISolate® (Irvine Scien-
tific, Santa Ana, CA, USA). In contrast to Percoll®, which is
a PVP-coated silica that can have deleterious effects on
sperm membranes [56], all these replacement products
contain silane-coated silica particles, are adjusted for the
osmolarity with polysucrose and have very low toxicity.
All these replacement products are non-irritating and are
approved for human in vivo use. The results of sperm prep-
aration using these new products compared with Percoll®
regarding recovery rate, motility, viability, normal sperm
morphology and velocity parameters like VAP or VCL vary
considerably among different working groups. While
Claassens et al. [61] and Söderlund and Lundin [62] did
not find differences in the recovery rate between Percoll®
and PureSperm®, Chen and Bongso [63], depending on
the number of layers included for the density gradient,
reported significantly higher values for PureSperm®. For
IxaPrep® it is even more confusing because Yang et al. [64]
found no difference to Percoll®, while Makkar et al. [14]
found the replacement substance more effective. On the
other hand, McCann and Chantler [65] as well as Ding et
al. [66] found Percoll® superior. These authors attribute
the better sperm quality obtained after the IxaPrep® prep-
aration to a significantly decreased production of nitric
oxide, which is regarded as sperm toxicant that reduces
motility [67]. This could be due to an activation of guan-
ylyl cyclase, thus increasing cGMP production, which
inhibits sperm motility [68]. On the other hand, nitric
oxide is also known to be a physiologic mediator for
vasodilatation, immunosuppression, neurotransmission
and cytotoxicity [69-72].
Regarding the other parameters such as motility, viability,
normal sperm morphology or velocity parameters like
VAP, the data currently available also vary considerably
among different working groups. The reason for this can
be attributed to the different conditions of the sperm sep-
aration, e.g. volume of semen to be separated, g-force,Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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centrifugation time or the number of layers of the gradi-
ent, and reflect the important role of the methodology.
Moreover, this also shows that these data cannot be
directly compared. Overall, the Percoll®-replacement
products are good and reasonable alternatives, and this
not only for the fact that Percoll® is no longer allowed to
be used for clinical purposes in assisted reproduction.
Glass wool filtration
During glass wool filtration, which has already been
described by Paulson & Polakoski in 1977 [17], motile
spermatozoa are separated from immotile sperm cells by
means of densely packed glass wool fibres. The principle
of this sperm separation technique lies in both the self-
propelled movement of the spermatozoa and the filtra-
tion effect of the glass wool. The success of this method is
directly linked to the kind of glass wool used [73]. Thus,
factors like the chemical nature of the glass (i.e. borate
glass, silicate glass or quartz glass), the surface structure
and charge of the glass wool, thickness of the glass wool
fibres or the pore size of the filter have to be taken into
consideration. In clinical practice, the glass wool, code
number 112, from Manville Fiber Glass Corp. (Denver,
CO, USA) or SpermFertil®  columns from Mello
(Holzhausen, Germany) have been tested extensively.
Potential risks of the technique such as damages of the
spermatozoa or the occurrence of glass wool fragments in
the filtrate essentially depend on the kind of glass wool
used and on the intensity of the washing prior to the
filtration.
Compared with the swim-up or migration-sedimentation,
glass wool filtration, just as density gradient centrifuga-
tion, is a technique that uses the whole volume of the ejac-
ulate and therefore yields a significantly higher total
number of motile spermatozoa [31,74]. Thus, it can also
be used for patients with oligo- and/or asthenozoosper-
mia [74]. Like density gradient centrifugation, glass wool
filtration also provides the advantage that the sperm sep-
aration can directly be performed from the ejaculate. Only
after the separation of the functional spermatozoa from
the immotile ones, leukocytes and debris, a centrifugation
step will be necessary to remove the seminal plasma. This
is an important aspect as this procedure reduces cellular
damage by reactive oxygen species. The advantages and
disadvantages of this method are summarized in table 4.
By means of glass wool filtration, it is even possible to pre-
pare motile spermatozoa from patients with retrograde
ejaculation (Henkel et al., unpublished). In these cases,
the procedure includes adjustment of the osmolarity of
the patient's urine to values of about 350 mOsmol/kg by
drinking water. Prior to the ejaculation, the patients are
requested to urinate most of the urine in the bladder. The
small amount of antegrade-produced ejaculate is col-
lected in a plastic beaker, while the retrograde fraction of
the ejaculate needs to be urinated immediately into a jar
with 50 ml culture medium containing human serum
albumin to dilute the urine, Finally, the urine/medium
mixture has to be centrifuged, resuspended in 3 to 4 ml of
fresh medium and filtrated on the glass wool column. As
constituents of the urine can damage the spermatozoa, a
speedy work-up of such ejaculates is mandatory.
In addition to the separation of spermatozoa, glass wool
filtration has been shown to eliminate leukocytes to an
extent of up to 90% [75]. Since leukocytes are frequent
even in normal ejaculates [76] and produce 100-times
more ROS than spermatozoa [32], this effect significantly
contributes to a reduction of free radicals in the ejaculate
[73,75]. This is of paramount importance for the func-
tionality of spermatozoa because the male germ cells are
particularly susceptible to oxidation by ROS because of
their extraordinary high content of polyunsaturated fatty
acids in their plasma membrane [33,77,78].
Another clinically interesting aspect related to glass wool
filtration is chromatin condensation, which has repeat-
edly been shown to be predictive of fertilization in vitro
[79-81]. Glass wool filtration [31] like the density gradi-
ent centrifugation with PureSperm® [82] or the migration-
sedimentation technique [44] significantly selects nor-
mally chromatin-condensed spermatozoa, while conven-
tional swim-up or Percoll®-centrifugation decrease this
Table 4: Advantages and disadvantages of the glass wool filtration.
Advantages Disadvantages
- simple to perform - a bit more expensive
- normally, recovery of spermatozoa with good motility - the filtrate is not as clean as it is with other sperm separation methods
- spermatozoa from ejaculates with a very low sperm density can be 
separated
- remnants of debris are still present
- good yield
- leukocytes are eliminated to a large extent
- reactive oxygen species are significantly reducedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
Page 7 of 22
(page number not for citation purposes)
sperm parameter. As human sperm chromatin condensa-
tion follows a seasonal rhythm, which even shows a shift
of about half a year on the southern hemisphere [83], this
might have a clinical impact on the results in IVF. Should
a patient be examined in winter when the quality of sperm
chromatin condensation is high [83] and referred to IVF
in summer when the percentage of normally chromatin-
condensed spermatozoa is significantly lower, IVF for this
patient might fail. Thus, for these patients a sperm separa-
tion by means of glass wool filtration, PureSperm® or
migration-sedimentation might be beneficial.
Glass beads
This method has been used for the preparation of hamster
spermatozoa for in vitro capacitation [84] and resulted in
an efficient, high yield selection of motile human sperma-
tozoa from semen [85]. However, there were concerns
regarding the possible spill over of beads into the insemi-
nation medium. As a result, the use of glass beads for
effective sperm preparation for assisted reproduction has
not widely been accepted.
Sephadex columns
In the early nineties sperm separation by means of Sepha-
dex beads emerged [18] and a commercial sperm separa-
tion kit based on this principle (SpermPrep®) has become
available. Compared to migration-sedimentation and
swim-up from pelleted semen it produced significantly
higher yields [86]. Moreover, morphologically normal
sperm cells could be enriched in the filtrate after Sperm-
Prep® separation as well as significantly higher pregnancy
rates for intrauterine insemination as compared with the
conventional swim-up method [87]. In a comparison
between SpermPrep® method and Percoll® centrifugation,
Percoll®  separated spermatozoa showed a significantly
higher percentage of normally chromatin-condensed and
morphologically normal spermatozoa [88]. However, the
fertilization rates reported by these authors were similar.
López et al. [89] used a prepacked PD-10 column contain-
ing Sephadex G-25 particles (Pharmacia Biotechnology,
Uppsala, Sweden), which is normally used to desalt pro-
teins in solutions, to separate human spermatozoa and
compared the results with the SpermPrep® method and
Percoll® centrifugation. The PD-10 column and density
gradient centrifugation in Percoll® yielded a comparable
number of spermatozoa and showed similar percentages
of morphologically normal spermatozoa after sperm sep-
aration. On the contrary, the SpermPrep® method resulted
in significantly lower values of sperm count and
morphology.
Transmembrane migration
Another alternative sperm separation technique that was
also developed in the late eighties is migration/filtration
of motile spermatozoa through a Nuclepore membrane
filter. These filters are unusual because their pores are
cylindrical and at right angles to the plane of the mem-
brane [90]. The spermatozoa, therefore, have straight
channels to swim through the membrane. Unfortunately,
these membranes had a very low ratio of the total cross-
sectional area of the pores to the overall membrane area.
Consequently, the yield is extremely low. Primarily, this
method was used for testing the motility of sperm popu-
lations treated with various pharmacological agents, but
not as a preparation method for assisted reproduction
[91].
Another approach of separating viable human spermato-
zoa by means of membranes was undertaken by Agarwal
et al. [19] using a membrane which has been developed
for selective removal of leucocytes (L4 membrane).
Besides a significant increase of motility, ejaculates fil-
tered through this membrane have been shown to contain
fewer leukocytes. This fact is, of course, of importance in
those cases that have increased numbers of leucocytes in
the ejaculate as a result of infections. Moreover, this mem-
brane seems to be selective for spermatozoa with normal
membrane integrity [92,93] and sperm producing low
amounts of reactive oxygen species [94]. However, despite
these advantages of the membrane it has never come into
practical clinical use for human assisted reproduction.
Improvement of sperm concentration in the 
fertilization well
Apart from the different sperm separation techniques to
increase the number of functional spermatozoa for
assisted reproductive techniques discussed above, trials
have been made to improve fertilization rates by modify-
ing the conditions of the co-culture of oocytes with sper-
matozoa. Micro-insemination techniques have especially
been developed for patients with sperm counts or asthe-
nozoospermia. One of the first who used such a method
for assisted reproduction were Ranoux and Seibel [95].
These authors used a microvolume straw to co-incubate
spermatozoa with the oocytes and incubated this straw
intravaginally, thus they called the technique intravaginal
culture (IVC). Giorgetti et al. [96] proposed a swim-across
technique in a medium that contains human follicular
fluid and found a significantly improved fertilization rate
for patients with motile sperm counts less than 1 × 106
spermatozoa/ml of semen. Fishel et al. [97] reported crit-
ically on the microdrop IVF and preferred microinjection.
On the other hand, Svalander et al. [98] presented encour-
aging results with a fertilization rate of 49.3% and a baby-
take-home rate of between 20–24.7%. Although this is
lower than the baby-take-home rate reported for conven-
tional IVF (27–31.7%), these authors recommended the
technique for moderate male factor infertility.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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This success of the technique may be dependent on the
volume of the microdrop as well as on the sperm concen-
tration. In this regard, Özgür et al. [99] developed a pre-
dictive model to calculate the therapeutically optimal
sperm concentration for a defined microvolume. This
might be explained by data of Özgür and Franken [100]
who showed that sperm-zona binding is dependent on
the sperm-zona collision rates, which is dependent on the
size of the microdrops itself. However, as the results of the
microdrop IVF were conflicting, and successes sporadic,
intracytoplasmic sperm injection (ICSI) has become the
method of choice in the treatment of severe male factor
infertility.
Immunological infertility and ART
Immunologic infertility due to sperm autoimmunity
afflicts 5–10% of infertile couples [101]. Normally, male
germ cells, which express surface antigens that are not
present on somatic and pre-meiotic cells, are shielded
from immuno-competent cells in the body by the blood-
testis barrier. This prevents an immunologic reaction.
However, in the event of a disintegration of the blood-tes-
tis barrier by infections, injuries or due to surgical
treatments, these actually "strange" surface antigens can
be exposed to the immune system. As a result, the body
produces antibodies against its own spermatozoa. On the
other hand, women can also produce anti sperm-antibod-
ies. One possible target for such antibodies is the human
sperm protein rSMP-B [102]. These antibodies can coagu-
late and immobilize the spermatozoa or can even be cyto-
toxic [103] and eventually lead to infertility as well as
reduced fertilization rates in assisted reproduction [104].
However, contradictory results that the presence of sperm
autoantibodies in female sera used for media in IVF does
not affect the IVF result are also reported [105].
In the past, it was thought that anti sperm-antibodies
could be eliminated just by washing them off. However,
as normal antigen-antibody reactions usually have affinity
constants between 107 and 109 l/mol, a simple washing
step will not suffice for removing these antibodies from
the sperm surface. As in men with sperm autoantibodies
not all spermatozoa are affected by the antibodies, Hint-
ing et al. [106] could significantly reduce the anti sperm-
antibodies as tested with the mixed antiglobulin reaction
test (MAR test) by using a swim-up technique with fetal
cord serum. The cumulative pregnancy rates of treatments
for intrauterine insemination (IUI) in cases of immuno-
logical infertility are reported between less than 10%
[107] and up to 25% [108]. Today, the method of choice
to treat severe cases of immunological infertility is IVF or
even ICSI where pregnancy rate of 30–40% per cycle can
be achieved.
In vitro treatment of spermatozoa
An alternative and/or complementary approach to sperm
preparation for ART in vitro by means of the above dis-
cussed sperm separation methods is the idea to treat the
spermatozoa in vitro in order to improve their functional-
ity, i.e. motility, or to supply a protective environment
with the purpose to maintain or improve their functional
capacity for successful fertilization. Many substances
including serum, peritoneal fluid and follicular fluid or
other chemically defined pharmacological substances like
progesterone, adenosine analogues or methylxanthins
have been proposed to stimulate human sperm functions.
The methodologies addressing the different aspects,
motility and sperm functions, ROS, and the reduction of
the visco-elastic properties of the semen are discussed
below.
Molecular structures of xanthine (A), caffeine (B), pentoxifyl- line (C) and 2-deoxyadenosine (D) Figure 1
Molecular structures of xanthine (A), caffeine (B), pentoxifyl-
line (C) and 2-deoxyadenosine (D).
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Improvement of motility and sperm functions
CAFFEINE
The use of xanthine (Fig. 1A) derivatives like the methylx-
anthines caffeine (1,3,7-trimethyl-2,6-dioxopurine) (Fig.
1B) and pentoxifylline (Fig. 1C) for the pharmacological
stimulation of sperm functions, especially for motility, is
well known. Garbers et al. [109] already suggested stimu-
lation of human sperm motility by caffeine. This sub-
stance is an inhibitor of the phosphodiesterase that leads
to increased cellular levels of cAMP. Considering that a
defective energy metabolism of the spermatozoa is also a
potential cause of male infertility, the use of motility stim-
ulating substances to improve sperm motility and there-
fore fertilization rates appeared reasonable.
Human spermatozoa can obtain energy from both glyco-
lysis and mitochondrial oxidative phosphorylation [110].
Thus, motility parameters such as mode of progression,
lateral head displacement or velocity of fresh and cryopre-
served spermatozoa significantly increased after stimula-
tion with caffeine due to augmented glycolysis and
fructolysis [111-113]. A small study including 6 patients
by Serres et al. [114] revealed that the stimulatory effect is
most obvious in patients with asthenozoospermia. How-
ever, early reports documented not only a stimulating
effect of caffeine, but also a time- and concentration-
dependent detrimental effect on the sperm plasma mem-
brane [115,116]. Moreover, spermatozoa pre-incubated
with caffeine showed a significant decrease in the percent-
age of penetrated zona-free hamster oocytes [117]. The
only study available [118] that investigated the effect of
caffeine in assisted reproduction using 42 oocytes from 21
women showed an increase in sperm motility but a signif-
icant decrease in the fertilization rates and embryo
development.
Direct incubation of mouse oocytes and embryos resulted
in a time- and concentration-dependent artificial parthe-
nogenic activation of the oocytes and a significant reduc-
tion of embryo cleavage rates [119]. As these data were
more disappointing than stimulating for the clinical use
of caffeine in assisted reproduction, it was further only
used for research purposes. A very recent prospective study
by Klonoff-Cohen et al. [120] investigated the daily caf-
feine consumption of 221 patients and its effects on the
outcome of IVF/GIFT treatments. According to these
authors, failed pregnancies were significantly associated
with the female's caffeine consumption. In addition, ges-
tational age at delivery decreased significantly in women
who consumed more than 50 mg/day. Male caffeine con-
sumption appeared to be a significant risk factor for mul-
tiple gestations but had no effect on sperm count, motility
or normal sperm morphology. An earlier study [121],
however, demonstrated a positive association between
coffee consumption and sperm concentration, motility
and abnormal sperm morphology in a total of 546 men.
In combination with smoking as further risk factor, sperm
motility and viability decreased significantly. Klonoff-
Cohen et al. [120] confirmed the embryotoxic effect of
caffeine causing delayed conception [122] or spontaneous
abortions [123] and concluded that the caffeine
consumption should be minimized prior to and during
an assisted reproduction treatment.
PENTOXIFYLLINE
Pentoxifylline (Fig. 1C) is another methylxanthine deriv-
ative, which is also, like caffeine, a non-specific inhibitor
of phosphodiesterase. In contrast to caffeine, the Food
and Drug Administration (FDA) approved pentoxifylline
for the administration to humans. The drug is used for sys-
temic treatments of patients with cardio-vascular diseases
(Trental® or Torental®). In addition, since its water solubil-
ity is higher than that of caffeine, this increases its usabil-
ity [124].
The beneficial effect of pentoxifylline on sperm motility
and motion characteristics like sperm velocity or hyperac-
tivity has repeatedly been described for both fresh
[112,125-129] and cryopreserved spermatozoa [128,130-
132]. The results on the stimulation of sperm motility are
conflicting. Yovich et al. [133], Rees et al. [112] and Lewis
et al. [134] found no effect in normozoospermic patients,
while others [133-136] observed a significant increase in
motility and the number of progressively motile sperma-
tozoa in patients with asthenozoospermia. This stimula-
tory effect can clearly be attributed to the increased
intracellular levels of cAMP. In the absence of the drug,
the cAMP content remained unchanged and correlated
only with hypermotility and the amplitude of the lateral
head displacement of the spermatozoa [137]. Cyclic AMP,
in turn, is believed to stimulate a cAMP-dependent kinase
[138], which itself induces sperm tail protein phosphor-
ylation [139] with subsequent increase in sperm motility
[140].
Apart from the effects on sperm motility, pentoxifylline is
also reported to augment acrosome reaction [141]. Nassar
et al. [142] demonstrated that this induction is not due to
a Ca2+-influx in the sperm cell, which is regarded to stim-
ulate acrosome reaction [143]. The intracellular [Ca2+]i
even decreased following the pentoxifylline treatment.
Since cAMP is intimately involved as a second-messenger
in the induction of acrosome reaction [144], an unspecific
inhibition of phosphodiesterases by this methylxanthine
will increase the intracellular cAMP levels and therefore
induce acrosome reaction. In addition, this drug also
improves the spermatozoa's zona pellucida binding abil-
ity [139,145,146]. However, it appeared that this binding
improvement to the zona pellucida is rather a result of the
increase in the sperm velocity parameters straight-lineReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
Page 10 of 22
(page number not for citation purposes)
velocity (VSL) and average path velocity (VAP) as these
parameters are indicators of progressive motility. There-
fore, these spermatozoa represent a sperm population
that did not initiate acrosome reaction with its character-
istic change in movement characteristics yet [147].
The benefits of a treatment with pentoxifylline prompted
its use in assisted reproduction programs. However, the
results reported in the literature are rather conflicting.
While Tasdemir et al. [148] and Tarlatzis et al. [149]
found an improvement in the IVF rate and saw a promis-
ing development in small studies comprising 51 and 43
patients, respectively. Others did not find differences
between the control and the treatment group in IVF and
intrauterine insemination [150-152]. Thus, it was con-
cluded that pentoxifylline should not be used indiscrimi-
nately [153]. On the other hand, pentoxifylline has been
successfully used to increase fertilization rates in bovine in
vitro fertilization [154] and as pre-treatment to stimulate
epididymal and testicular sperm motility for ICSI
[155,156]. Should the results of Numabe et al. [154] be
confirmed, this could be a promising approach to
improve fertilization rates especially for endangered
species.
The conflicting results on the effectiveness of a pentoxifyl-
line treatment raised the question of the embryotoxicity of
this substance, especially since possible pentoxifylline-
induced adverse effects on spermatozoa [157] and mouse
embryo development [158,159] have been reported. In
contrast, Lacham-Kaplan & Trounson [160] did not
observe such negative effects on embryonic development
after insemination of the oocytes with spermatozoa incu-
bated in 3 mM pentoxifylline. Finally, short-term incuba-
tion of spermatozoa with subsequent washing of the male
germ cells did not produce such adverse effects in intrau-
terine insemination or ICSI (Henkel et al., unpublished)
[156]. An alternative approach to increase sperm motility
or the number of motile spermatozoa was to administer
the drug orally over period of 3 to 6 months [161]. In a
placebo-controlled study including 47 normozoospermic
men with idiopathic asthenozoospermia, Merino et al.
[162] showed a significant increase in progressive motility
in men who received 1,200 mg of pentoxifylline per day
over 6 months. Clinical data about fertilization and preg-
nancy, however, are still not available.
Another important point that must not be underesti-
mated in explaining the controversial effects of pentoxifyl-
line is the fact that this drug is an unspecific inhibitor of
the phosphodiesterase (PDE). Considering that eleven
different families of this enzyme have been described
[163], of which PDE-1 and PDE-4 are present in human
spermatozoa and stimulate different sperm functions, i.e.
acrosome reaction and motility, respectively [164], an
unspecific inhibition of the PDE's will obviously result in
both, stimulation of motility and acrosome reaction.
Depending on the conditions and most importantly on
the time of stimulation and the concentration of pentoxi-
fylline in the medium, over-stimulation will definitely
result in a too early acrosome reaction. Hence, over-stim-
ulated spermatozoa for an IUI or IVF treatment will not
fertilize oocytes because they are no longer able to bind to
the zona pellucida. This dilemma might be overcome by
the use of a non-embryotoxic PDE-4 inhibitor to stimu-
late sperm motility only. Unfortunately, to our knowl-
edge, no further progress has been made in this regard. For
ICSI, this problem is not relevant as spermatozoa bypass
all physiological barriers because they are directly injected
into the oocytes.
2-DEOXYADENOSINE
2-Deoxyadenosine (2-DA) (Fig. 1D) is an adenosine
derivative that is not a phosphodiesterase inhibitor like
pentoxifylline or caffeine. Like these substances, 2-DA is
also a potent stimulant of sperm motility [165,166]. The
molecular mechanism of motility stimulation, however,
works via an A2-receptor-mediated activation of adenylate
cyclase [167], which in turn is thought to enhance the
intracellular cAMP concentration [168,169]. Because of
this characteristic, the use of 2-DA in assisted reproduc-
tion programs has been discussed. Other studies, how-
ever, failed to detect a responsive cAMP activity and either
stimulatory or inhibitory G-proteins in spermatozoa
[170,171]. In addition, Rivkees [172] could not detect
A2a- and A2b-receptor gene expression in the rat testis.
This would imply that these stimulatory receptors are
either not present or, at least, at very low levels. On the
other hand, the cAMP-inhibitory A1-receptor has a capac-
itative effect on human spermatozoa when stimulated
with an agonist [173]. While Imoedemhe et al. [174] in an
internally controlled prospective study showed signifi-
cantly higher fertilization rates after sperm stimulation
with 2-DA and hence suggested further evaluation of the
drug in assisted reproduction programs, Tournaye et al.
[150] recommends a careful evaluation and selection of
the patients before the treatment with motility stimulants.
Recently, 2-DA and pentoxifylline have been suggested for
sperm stimulation in an in vitro culture of testicular tissue
in order to obtain motile spermatozoa for ICSI [175].
However, it seems rather questionable whether a treat-
ment of spermatozoa with 2-DA for the purpose to ferti-
lize oocytes should be recommended because there is also
evidence that it has adverse effects on embryos. In this
regard, 2-DA significantly reduced the cleavage of mouse
embryos beyond the 2-cell stage [160]. In addition, 2-DA
and cAMP have been shown to exert cytotoxic effects by
inducing G1 cell cycle arrest [176]. In view of this, a ther-
apeutic clinical use of stimulants that increase the intrac-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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ellular cAMP levels should be evaluated very carefully. At
least, a very careful washing of the spermatozoa is
mandatory.
KALLIKREIN
A substance, which has been discussed very controver-
sially regarding its stimulatory effect on sperm motility
and sperm functions during the past ten years, is kal-
likrein. Despite all components of the kallikrein-kinin sys-
tem are present in the male and female genital tract
[177,178] and the localization of the bradykinin B2-recep-
tor in rat testis [179,180], the function of the kallikrein-
kinin system for male reproductive function is still
unclear. The prostate-specific human glandular kallikrein,
which is about 500-times less effective than tissue kal-
likrein, is present in human seminal plasma [181]. In
addition, in vitro studies reported a positive effect of kal-
likrein and its cleavage products, the kinins, on sperm
functions including motility [182,183]. This suggests an
involvement of this enzyme or bradykinin in the male
reproductive system. Gerhard et al. [184] reported a sig-
nificant improvement of sperm motility when using kal-
likrein in an artificial insemination program where 172
patients were randomly assigned to the treatment and
control group. However, the penetration distance of
sperm in cervical mucus was significantly lower and was
regarded as cause for the lower pregnancy rates in this
group of patients. In contrast, Schill et al. [185] found an
increased cervical mucus penetrability of human sperma-
tozoa following treatment of with hog pancreatic kal-
likrein and bradykinin.
The results regarding ART are as contradictory as the
results on in vitro stimulation of spermatozoa. Schill and
Littich [186] reported an increased pregnancy rate in
intrauterine insemination following stimulation of sper-
matozoa with kallikrein in a cross-over blind study in 48
asthenozoospermic and oligoasthenozoospermic ther-
apy-resistant patients in 468 inseminations. All patients
included in that study were shown to respond to this
treatment beforehand. On the other hand, there are in
vitro studies [187,188] and double-blind placebo-control-
led studies [189,190] that did not show any effect of kal-
likrein and bradykinin on sperm motility or sperm count.
Miska et al. [191] showed that porcine pancreatic kal-
likrein, which is taken orally, is absorbed in unaltered
form by the intestine. In the light of the recent data by
Monsees et al. [178-180] obtained in the rat, the kal-
likrein-kinin system in the male reproductive tract seems
to play a role in the regulation of Sertoli cell function, the
local regulation of spermatogenesis or in the function of
the seminiferous tubules.
BICARBONATE
Another interesting approach to improve sperm motility
and thus sperm recovery from the ejaculate that has not
yet been used for clinical application in assisted reproduc-
tion is the stimulation of the sperm cell's kinematics by
bicarbonate [192]. It is well known that bicarbonate is a
major secretory component of the fallopian tube that
stimulates sperm respiration [193], and is also postulated
to be beneficial for fertilization [194]. The latter appears
to be supported by its effect on capacitation, induction of
acrosome reaction [192,195,196] and hyperactivated
motility, which in turn is required for successful zona pen-
etration in the hamster [197]. These physiological
changes, especially acrosome reaction and hyperactiva-
tion, require the influx of Ca2+ into the spermatozoa.
Acrosome reaction is absolutely dependent on the pres-
ence of extracellular calcium [195]. Recent work by Wen-
nemuth et al. [198] showed that bicarbonate also
facilitates the opening of voltage-gated Ca2+-channels,
which are eventually involved in the increase in flagellar
beat frequency shortly after stimulation. Thus, bicarbo-
nate is an important mediator of sperm cell function.
Therefore, media with enhanced levels of this anion might
be helpful for sperm preparation and assisted reproduc-
tion. Henkel et al. [199] showed that sperm preparation
by using a medium containing high levels of bicarbonate
resulted in a significantly higher progressive motility as
well as sperm recovery. In addition, the co-incubation of
human spermatozoa with zonae in this medium resulted
in a significantly increased zona binding of the spermato-
zoa. Jaiswal and Majumder [200] made similar observa-
tions in testicular and epididymal spermatozoa from goat
and ram. While theophylline, a phosphodiesterase inhib-
itor, and epididymal fluid only induced a non-progressive
flagellar movement of these initially immotile sperm, the
addition of bicarbonate induced forward motility in 16 to
40% of the sperm cells. This motion stimulating effect of
bicarbonate, which otherwise only appears in a subpopu-
lation of the spermatozoa [201], is mediated by an activa-
tion of adenylate cyclase [202,203] with subsequent
increased levels of cAMP, which in turn stimulate protein
kinase A [204] and results in protein phosphorylation
[205]. H89, a highly specific inhibitor of protein kinase A,
significantly inhibited bicarbonate induced sperm motil-
ity and indicates the importance of this enzyme for sperm
motility [201].
Considering motility and acrosome reaction as important
sperm functions and bicarbonate as mediator as well as
the aspect that this anion is non-toxic as other motility
stimulants, it appears tempting to use a high bicarbonate
medium not only for diagnostic purposes [199], but also
in a clinical approach to improve sperm motility and
functions for assisted reproduction. However, as elevatedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
Page 12 of 22
(page number not for citation purposes)
pH levels can disturb the mitotic spindle, a treatment of
oocytes with bicarbonate should be performed with high
care.
CHELATORS
In a very recent approach, Wroblewski et al. [106] investi-
gated the influence of different metal chelators, i.e. DL-
penicillamine, 2,3-dimercaptopropan-1-sulfonate and
meso-2,3-dimercapto-succinimic acid, on human sperm
motility in vitro. These authors showed that the percent-
age motility and velocity, even of swim-up separated sper-
matozoa, can be enhanced by incubation with these
chelators, and speculate of a possible future use of such a
procedure to improve fertilization rates in IUI or IVF.
The proposed mechanism of this motility enhancement is
the removal of the element zinc from the outer dense
fibres (ODF), which are functionally essential substruc-
tures in the mammalian sperm flagellum. During sper-
miogenesis, cysteine and zinc are incorporated in
spermatozoa [207]. In human spermatozoa, zinc is local-
ized in the flagellum to an extent of 93–97% [208], espe-
cially in the ODF. When incorporated in the ODF, zinc is
first associated with the sulfhydryl groups of cysteine by
formation of relatively stable zinc-thiol complexes [209]
in order to protect ODF from premature oxidation [210].
This trace element is later removed from the sperm to an
extent more than 60% during epididymal sperm matura-
tion [207,211]. Thereafter, the sulfhydryl groups are oxi-
dized to disulphide-bridges that stabilize and stiffen the
ODF [212], which in turn leads to a better energy conver-
sion and therefore to better motility including forward
progression [213,214].
Latest research from our working group, however, showed
that at least DL-penicillamine and 2,3-dimercaptopropan-
1-sulfonate are not suitable for clinical use as both chela-
tors alter the sperm's responsiveness to the induction of
acrosome reaction (Henkel et al., unpublished). Thus, it
remains to be seen whether or not other chelators will not
show such adverse effects.
PLATELET-ACTIVATING FACTOR (PAF)
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyc-
erol-3-phosphocholine) is a biologically highly potent
signalling ether phospholipid, which was first described
by Benveniste et al. [215]. Apart from its multiple func-
tions on circulation, inflammation, systemic vasodilata-
tion, pulmonary bronchiole constriction, platelet and
neutrophile activation, cardiac ischemia, tissue rejection,
gastric ulcer and development [216-218], it is reported to
be a cellular mediator in reproduction. Here, PAF appears
to be involved in implantation [219] and may reflect
embryo health and viability [220,221]. Moreover, PAF has
been found in spermatozoa of different species like rabbit,
mouse, pig, rhesus monkey and human [221-226].
Several authors reported positive effects on motility,
capacitation, acrosome reaction and oocyte penetration
[227-230]. PAF antagonists can inhibit its positive actions
on sperm function [231]. The sperm content of PAF in the
species investigated is positively related with the fertility
status of the male [232]. Reinhardt et al. [233] provided
evidence for a PAF receptor on human spermatozoa at the
midpiece and proximal sperm head suggesting that the
action of PAF is receptor-mediated, which does not result
in increased levels of intracellular cAMP concentrations
[234,235]. However, PAF binds to the surface receptor
and activates a phospholipase, which in turn converts dia-
cylglycerol (DAG) to inositol triphosphate (IP3), and thus
increases the intracellular [Ca2+]i concentration that can
either be released from intracellular stores or by an extra-
cellular Ca2+-influx via Ca2+-channels. This intracellular
Ca2+-increase may thus be responsible for the induction of
acrosome reaction [236]. However, although the exact
molecular mechanism of the action of PAF has not yet
been elucidated in detail, these positive effects led the use
of PAF in assisted reproduction. Recently, in a prospective,
randomized, blinded study in 143 patients, Roudebush et
al. [237] presented data showing that pregnancy rates in
intrauterine insemination were significantly improved
after separating the spermatozoa with a medium contain-
ing PAF. The advantage of such a treatment is that PAF is
a natural substance that is non-toxic as it is with many
other motility stimulators.
Selection of live spermatozoa from a completely immotile 
sperm population prior to ICSI
An important aspect of sperm selection and the improve-
ment of sperm functions are reflected by the selection of
spermatozoa for ICSI from extremely poor semen quality.
In this regard, special emphasis should be laid on the
selection of spermatozoa from a completely immotile
sperm population. For the success in ICSI it is important
to inject viable spermatozoa. Normally, this distinction is
made by the sperm's most obvious function, motility; a
motile spermatozoon is live. However, in this particular
group of patients this distinguishing mark is void and sci-
entists were urged to find non-harmful methods that
identify live spermatozoa in a population of immotile
sperm and that are suitable for the use in ICSI, i.e. that do
not harm the oocyte. To date, two different approaches for
the distinction between live and dead spermatozoa have
been pursued; (i) the initiation of motility as sign of vital-
ity by means of stimulants and (ii) the identification of
live spermatozoa according to their membrane integrity
by means of the hypo-osmotic swelling test (HOS test).Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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The initiation of motility in an immotile sperm popula-
tion is just a consequence of the idea to improve motility
by means of the PDE inhibitor pentoxifylline as described
above. As pentoxifylline stimulates motility without alter-
ing the sperm membrane [238] it appeared as an ideal
substance to initiate motility in immotile spermatozoa.
This method was successfully used to identify live testicu-
lar and epididymal spermatozoa and live births are
reported [155,156,239].
The other option to identify spermatozoa suitable for ICSI
is to detect their viability by means of their membrane
integrity by the HOS test, which has originally been
described by Jeyendran et al. [240]. To our knowledge,
this method was first proposed by Pike et al. [241]. In a
small study group of 7 patients these authors showed
markedly improved fertilization rates when oocytes were
injected with HOS test-positive sperm. Others who also
demonstrated significantly higher pregnancy rates eventu-
ally confirmed these positive results [242-245]. Eventu-
ally, the basic technique has been modified and
simplified. All of these modifications resulted in the same
promising outcome, significantly elevated fertilization
and pregnancy rates [246-249]. Buckett [250] suggested a
combined HOS test with the eosin-nigrosin stain as a rou-
tine test in the andrological laboratory diagnosis to pre-
dict the spermatozoa's fertilizing ability in patients with
severe and complete asthenozoospermia.
At this point, however, it is also important to mention the
possible consequences of fertilization of oocytes with
sperm by ICSI. As sperm motility is also significantly neg-
atively correlated with the production of reactive oxygen
species in the spermatozoa themselves and positively cor-
related with sperm DNA fragmentation [251], the proba-
bility to select such DNA-damaged spermatozoa for ICSI
is far higher. According to present knowledge, sperm DNA
fragmentation might not only cause an impaired embry-
onic development and early embryonic death [252-254],
but also an increased risk of childhood cancer in the off-
spring [255,256]. The latter is due to the vulnerability of
human sperm DNA during late stages of spermatogenesis
and epididymal maturation. At this stage, DNA repair
mechanisms have been switched off, resulting in a genetic
instability of the male germ cells [257], especially on the
Y-chromosome resulting in male-specific cancers [258].
Therefore, a careful examination and counselling of the
patients seems mandatory, and fertilization with ICSI
should not be performed at all cost.
Scavengers for reactive oxygen species (ROS)
In order to maintain cellular polarity and function, sper-
matozoa contain an extraordinary high amount of poly-
unsaturated fatty acids, particularly docosahexanoic acid,
which has six double bonds per molecule in the plasma
membrane. This, in combination with the sperm cell's
lack of defence systems, which is due to the obvious defi-
ciency in cytoplasm, and therefore its inability to repair
membrane damages effectively renders spermatozoa par-
ticularly susceptible to oxidative stress [78]. As sperm
functions are membrane functions, oxidative damage for
any method of assisted reproduction should be reduced to
a minimum in order to obtain a maximum of functionally
competent male germ cells and to achieve fertilization
and pregnancy. Apart from the different sperm separation
methods (as discussed above), which also have a signifi-
cant influence on the ROS production of the spermato-
zoa, another option to improve sperm functionality and
motility is to reduce the detrimental effects of reactive oxy-
gen species on spermatozoa in vitro or in vivo by means
of scavenging these highly reactive molecules.
In vivo, spermatozoa depend on scavenging systems pro-
vided by the seminal plasma, which is the biological fluid
that contains more antioxidant substances than anyone
else does. The most important natural antioxidants in
seminal plasma seem to be vitamin C and E [259,260],
superoxide dismutase [261], uric acid [262], glutathione
[263] or the polyamine spermine that acts directly as a free
radical scavenger [264]. Patients with fertility problems
show reduced levels of the antioxidative capacity of the
seminal plasma [265-267]. Thus, in the context of oxida-
tive damage of sperm function not only an excessive ROS
production by either leukocytes [268] or the spermatozoa
themselves [75,269], but also the provision of a sufficient
protective antioxidative system in the male genital tract,
including the seminal plasma and the female genital tract
is of paramount importance. In attempts to tackle the
problem of oxidative stress, spermatozoa are either
treated with different antioxidants in vitro or the patients
are treated with antioxidative drugs.
GLUTATHIONE / N-ACETYL-L-CYSTEINE
As sulfhydryl groups (SH-groups) play an important role
in sperm metabolism and the antioxidative defence, and
glutathione (γ-glutamyl-cystenyl-glycine) is a natural,
highly effective reducing agent, this substance has been
tried as a tool to treat male infertility. In a placebo-con-
trolled, double-blind study, in which 20 patients were
daily injected with 600 mg glutathione, Lenzi et al. [270]
showed a significant increase in sperm motility, percent-
age of progressive motility and normal sperm morphol-
ogy. For in vitro treatment of spermatozoa with
glutathione during sperm separation, contradictory
results have been published. Following swim-up prepara-
tion of human spermatozoa in the presence of glutath-
ione Griveau & Le Lannou [271] found an improved
acrosome reaction and 24 hours-motility on the same
level as for Percoll® gradient centrifugation and suggest
that glutathione has a therapeutic potential. In contrast,Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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Donnelly et al. [272] provided data indicating that this
drug has no significant effect on progressive motility, nei-
ther by itself, nor in combination with hypotaurine. How-
ever, the treatment still afforded a significant protection
against ROS-induced DNA damage. Unfortunately, so far
only very few studies were undertaken in order to treat
male infertility using glutathione in vitro or as a treatment
for patients. In the human system, a medium based on
human tubular fluid supplemented with glucose, taurine
and glutathione failed to improve the clinical outcome,
fertilization or pregnancy. The morphological quality of
the embryos was even lower than in the same medium
supplemented with glucose and without phosphate [273].
In the porcine and bovine system a positive effect on in
vitro maturation of oocytes and blastocyst development, if
the spermatozoa were treated with glutathione [274-276]
was shown.
Another approach to treat oxidative stress-related male
infertility was performed by Oeda et al. [277]. These
authors used N-acetyl-L-cysteine (ACC), a water-soluble
and non-toxic drug that is used in pulmonary diseases
because of its strong effect in decreasing the viscosity of
sputum by sulfhydryl-disulfide interchange reaction
[278]. In addition, it was shown that the levels of glutath-
ione in the epithelial lining fluid recovered to normal val-
ues after administration of ACC in patients with
idiopathic fibrosis of the lung, suggesting that ACC may
act as a precursor of glutathione and thus facilitate its bio-
genesis [279,280]. In the human ejaculate, ACC revealed
a dose- and time-dependent significant reduction of the
ROS production [277]. In addition, the substance signifi-
cantly improved motility and did not have adverse effects
on viability and acrosome reaction. On the other hand,
Hughes et al. [281] demonstrated that the addition of
ACC to a sperm separation medium induced sperm DNA
damage. In a clinical study, Comhaire et al. [282] treated
27 infertile men orally with ACC and showed a significant
reduction of ROS. Moreover, significant increases were
found for acrosome reaction, the proportion of polyun-
saturated fatty acids of the phospholipids and for the
sperm count in oligozoospermic men. However, sperm
motility, morphology and the pregnancy rate seemed to
be unaltered. Whether or not this is due to the elevated
acrosome reaction or the small number of patients
included or to a reduced DNA integrity cannot be deter-
mined yet. This is a rational approach to treat male factor
infertility, which should be followed up in a bigger study.
VITAMINS
Apart from glutathione, vitamins C (ascorbate) and E are
natural antioxidants in cells and tissues where ascorbate
scavenges highly reactive molecules in the watery phase,
i.e. cytoplasm and surrounding liquids, and vitamin E is
effective in the lipid phase, i.e. the membranes. In order to
improve sperm functions in vitro, culture media were sup-
plemented with ascorbate and vitamin E. While Verma &
Kanwar [283] observed a dose-dependent improvement
of motility and viability accompanied by a decrease in
malondialdehyde production following vitamin E supple-
mentation, Donnelly et al. [284] did not show a beneficial
effect of neither ascorbate nor vitamin E on sperm motil-
ity. Different motility parameters like curvilinear velocity
or linearity were even significantly decreased after the
treatment. ROS production was significantly reduced
whereas the baseline in DNA damage remained unaltered
[285]. The simultaneous addition of vitamin C and E to
the sperm preparation medium actually induced sperm
DNA damage. These negative results of in vitro supple-
mentation with vitamins on human sperm function
appear plausible, as the lower levels of ascorbate in the
seminal plasma in asthenozoospermic patients [266] can
be regarded as a consumption of this antioxidant in vivo.
Thus, the oxidative damage of the spermatozoa leading to
reduced motility is most probably already set in the testis
or epididymis and cannot be repaired by such treatment
in vitro.
This consideration is supported by in vivo studies in rab-
bits, boars and in the human, where vitamin E supple-
mentation resulted in improved sperm functions and a
reduced production of free radicals [282,286-288]. How-
ever, there are also negative reports on the effect of vita-
min supplementation. In the human, Rolf et al. [289] did
not find changes in semen parameters of 31 astheno-
zoospermic and moderate oligoasthenozoospermic
patients treated with high doses of vitamin C and E in a
randomized, placebo-controlled, double-blind study.
Likewise, no positive effects on semen volume, pH or
sperm motility were observed following a dietary vitamin
E administration in the cock [290]. The reproductive per-
formance of the treated cocks was even negatively influ-
enced. These contradictory results show that neither the
exact mechanism and site of action, nor the indication for
a successful antioxidative treatment of patients are clear.
In addition, the action of genital tract inflammations has
not yet been taken into consideration. As leukocytes pro-
duce enormous amounts of free radicals [32] and their
specific impact on sperm function remains to be clarified,
more research must be carried out in order to obtain a
rational antioxidative therapy for male factor patients.
PENTOXIFYLLINE
Besides the effects of pentoxifylline on sperm motility and
acrosome reaction discussed above, this PDE inhibitor
has also effects on ROS. It has repeatedly been shown that
pentoxifylline significantly reduces the superoxide release
of human spermatozoa following phorbol myristate ace-
tate stimulation [291,292]. This effect is possibly due to
the reduction of the formation of endoperoxides as aReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/108
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consequence of the elevated cAMP levels that inhibit the
cyclo-oxygenase within the arachidonic pathway [292].
Contradictory results, however, were obtained regarding
lipid peroxidation. While Gavella & Lipovac [293] found
elevated levels of malondialdehyde after pentoxifylline
treatment and rather warned of its use in assisted repro-
duction, McKinney et al. [294] could not confirm these
findings. In a comparative study, Okada et al. [295] con-
firmed the ROS scavenging and motility stimulating effect
of pentoxifylline in vitro in 15 patients and 18 controls,
respectively. However, in vivo pentoxifylline at low dos-
ages (300 mg per day) failed to decrease ROS generation
and to increase motility. On the other hand, at high dos-
ages (1,200 mg per day), motility and beat cross frequency
were increased but the drug still did not have a beneficial
effect on sperm fertilizing ability.
Reduction of visco-elasticity of the ejaculate
In most mammals, semen coagulates shortly after ejacula-
tion and liquefies again later on. In the human, liquefac-
tion takes place within 5–20 minutes after ejaculation.
While so-called coagulation proteins like semenogelin or
fibronektin, which derive from the seminal vesicle, pro-
mote coagulation, seminolysis is caused by a prostate-
derived serine-proteinase, prostate-specific antigen (PSA)
[296]. However, in some cases viscosity of the semen
remains high and can be a cause for male infertility. It is
also important to differentiate between ejaculates that
have an excessive viscosity and such ejaculates that failed
to liquefy [107]. As highly viscous semen can reduce
sperm motility thus being a cause for male infertility, it is
necessary in the clinical set-up of assisted reproduction
either to reduce semen viscosity or to liquefy the ejaculate
artificially. For this, a few methods are available. Mixing
the semen with medium is the easiest way but will not
work sufficiently in cases of excessive semen viscosity.
Another method that was suggested in the past is to force
the viscous seminal fluid through a narrow-gauge needle.
However, considering the severe damage that this method
causes to the spermatozoa including immotility, it cannot
be recommended at all. It is therefore rather advisable to
liquefy such ejaculates enzymatically by using a 0.2%
solution of α-amylase. Several other enzymes like α-chy-
motrypsin, lysozyme or hyaluronidase have also been
described for this purpose. Recently, a special trypsin-
based dissolving solution, SpermSolute, has been
reported [297]. However, as these enzymes can also dam-
age spermatozoa, special care should be taken to remove
the enzymes by washing procedures as soon as liquefac-
tion is completed.
Concluding remarks
In conclusion, there are a number of different sperm sep-
aration methods available, which can be applied, even in
combination with pharmacological substances to
stimulate sperm functions or to protect the male germ
cells from the detrimental influence of free radicals. There-
fore, in patients with elevated ROS levels in the ejaculate
or with proven or suspected genital tract inflammations,
the conventional swim-up technique should certainly not
be the method of choice, but rather more gentle methods
like density gradient centrifugation, glass wool filtration
or migration-sedimentation. A supplementation of the
sperm separation medium with protective substances can
be considered. It is also of paramount importance to dis-
criminate between various patient groups including the
consideration of seasonal changes of semen and sperm
parameters. For the improvement of the percentage of
normally chromatin-condensed spermatozoa, for
instance, glass wool filtration or migration-sedimentation
should be preferred. In order to liquidize viscous semen
samples, one should absolutely refrain from forcefully
aspirating semen through narrow gauge needles as this
procedure severely damages the spermatozoa. Instead, an
enzymatic liquidization with subsequent washing of the
spermatozoa should be preferred. Thus, the sperm separa-
tion method must specifically be chosen in every individ-
ual case and consideration should be given for treating the
patient pharmacologically in vivo. This obviously requires
a careful andrological work-up and examination of male
partners of infertile couples.
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